Skip to main content

Janus kinase 3

The JAK3 gene provides instructions for making a protein that is critical for the normal development and function of the immune system. The JAK3 protein is part of a signaling pathway called the JAK/STAT pathway, which transmits chemical signals from outside the cell to the cell's nucleus. Signals relayed by the JAK3 protein regulate the growth and maturation of certain types of white blood cells (lymphocytes) called T cells and natural killer cells. In addition, JAK3 is important for the normal maturation of another type of lymphocyte called B cells. T cells, B cells, and natural killer cells attack bacteria, viruses, and fungi and help regulate the entire immune system.

Video picks for Genes
Video library

Normal function

The JAK3 gene provides instructions for making a protein that is critical for the normal development and function of the immune system. The JAK3 protein is part of a signaling pathway called the JAK/STAT pathway, which transmits chemical signals from outside the cell to the cell's nucleus. Signals relayed by the JAK3 protein regulate the growth and maturation of certain types of white blood cells (lymphocytes) called T cells and natural killer cells. In addition, JAK3 is important for the normal maturation of another type of lymphocyte called B cells. T cells, B cells, and natural killer cells attack bacteria, viruses, and fungi and help regulate the entire immune system.

Conditions referring to this gene or chromosome

Other names

JAK-3

JAK3_HUMAN

JAKL

Janus kinase 3 (a protein tyrosine kinase, leukocyte)

L-JAK

leukocyte Janus kinase

LJAK

tyrosine-protein kinase JAK3

Patient picks for Genes

Related patient information and medicines

Pompholyx

Patient information leaflet

Pompholyx

Its effectiveness for pompholyx is still being studied, so it is not recommended yet. Dapilumab : this medication is used for a type of eczema called atopic dermatitis. In some cases it has been shown to be helpful for the treatment of pompholyx. Janus Kinase (JAK) inhibitors : these medications, available as creams or pills, target specific.

Juvenile idiopathic arthritis

Patient information leaflet

Juvenile idiopathic arthritis

Psoriasis, eye inflammation and bowel inflammation may ... ServiceUpsellPlaceholder How is juvenile idiopathic arthritis diagnosed. The diagnosis of juvenile idiopathic arthritis (JIA) is based on the symptoms and an examination by your doctor. Options include: Etanercept Etanercept Tocilizumab Infliximab Abatacept Adalimumab Tofacitinib is.

Muscular dystrophy

Patient information leaflet

Muscular dystrophy

Becker's muscular dystrophy (BMD) BMD is similar in many ways to DMD, but is less severe. Also, if a child has delayed motor milestones (as mentioned above), a doctor may advise testing for MD, even though the problem could be due to anot... MD may be diagnosed using one or more of the following tests: A blood test Blood tests for creatine kinase.

Glycogen storage disorders

Patient information leaflet

Glycogen storage disorders

Glycogen storage disorders are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Symptoms include weakness,.

Primary liver cancer

Patient information leaflet

Primary liver cancer

It is not likely to be curative for primary liver cancer but may shrink the tumour down to slow the progression of the disease. There are new medicines being developed for the treatment of liver cancer. For example, sorafenib is a type of medicine called a multi-targeted kinase inhibitor. It interferes with the growth of cancer cells. Research has.

Myelofibrosis

Patient information leaflet

Myelofibrosis

...affecting the bone marrow and its blood cell productionThe gene mutation that occurs in most people affected by myelofibrosis is a mutation in Janus Kinase 2 (JAK2). Dr Sarah Jarvis, December 2021 NICE guidance on drug treatments for myelofibrosis Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis The National.

Article history

The information on this page is written and peer reviewed by qualified clinicians.
  • 18 Aug 2020 | Latest version
  • 1 Aug 2017 | Originally published

Join the conversation

Share your thoughts or experiences with others in our patient communities.

Disclaimer: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.

Online pharmacy, treatments and health services

Simple access to trusted treatments and health services online.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment

Sign up to the Patient newsletter

Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.

Please enter a valid email address

By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.